[
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) Collaborates With Antengene For Promising Cancer Therapy Evaluation",
    "summary": "In a recent development, Antengene Corporation Limited announced a global clinical collaboration with Merck (NYSE:MRK) to evaluate ATG-022 in combination with KEYTRUDA®, which could enhance Merck's oncology portfolio. Despite this collaboration and other positive product-related announcements, Merck’s stock price was relatively flat over the past month at a 1% decline. During this time, the broader market posted gains, driven by easing trade concerns and strong corporate earnings. The...",
    "url": "https://finnhub.io/api/news?id=628cfaaad2e412f93f1147b37708f342e59714e63d121055fddca620f6dce4c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747763271,
      "headline": "Merck (NYSE:MRK) Collaborates With Antengene For Promising Cancer Therapy Evaluation",
      "id": 134628369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In a recent development, Antengene Corporation Limited announced a global clinical collaboration with Merck (NYSE:MRK) to evaluate ATG-022 in combination with KEYTRUDA®, which could enhance Merck's oncology portfolio. Despite this collaboration and other positive product-related announcements, Merck’s stock price was relatively flat over the past month at a 1% decline. During this time, the broader market posted gains, driven by easing trade concerns and strong corporate earnings. The...",
      "url": "https://finnhub.io/api/news?id=628cfaaad2e412f93f1147b37708f342e59714e63d121055fddca620f6dce4c5"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons Why Japan's Record Bond Yield Spike Matters",
    "summary": "Japan's bond yield surge hints at global market risks. See how it impacts U.S. Treasuries, the yen, and top investments like Toyota and Sony.",
    "url": "https://finnhub.io/api/news?id=7aa7a5385b694ca435ab7b1f935d5d6bd903354ebc7282f4d9c68563cb9c998b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747744205,
      "headline": "3 Reasons Why Japan's Record Bond Yield Spike Matters",
      "id": 134611311,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161558032/image_2161558032.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Japan's bond yield surge hints at global market risks. See how it impacts U.S. Treasuries, the yen, and top investments like Toyota and Sony.",
      "url": "https://finnhub.io/api/news?id=7aa7a5385b694ca435ab7b1f935d5d6bd903354ebc7282f4d9c68563cb9c998b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival",
    "summary": "Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival",
    "url": "https://finnhub.io/api/news?id=f66604d8d6de5ec076b6cd42f3bea6990511fc9586482bb59cbabb3c06b6753e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747739520,
      "headline": "Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival",
      "id": 134613538,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival",
      "url": "https://finnhub.io/api/news?id=f66604d8d6de5ec076b6cd42f3bea6990511fc9586482bb59cbabb3c06b6753e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid.",
    "summary": "Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid.",
    "url": "https://finnhub.io/api/news?id=8041f6e263e65940f62a0bc1086feba2cf330ac1a51528470fbb567de7c24c6f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747737960,
      "headline": "Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid.",
      "id": 134613539,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid.",
      "url": "https://finnhub.io/api/news?id=8041f6e263e65940f62a0bc1086feba2cf330ac1a51528470fbb567de7c24c6f"
    }
  }
]